Cancer

May 4, 2023

Better adenoma detection

Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans.

April 27, 2023

Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

April 26, 2023

VICC Scientific Retreat focuses on emerging technologies

The Vanderbilt-Ingram Cancer Center 24th Annual Scientific Retreat will be held from 8:30 am to 3 pm, May 23, in the Vanderbilt Student Life Center.

From left, Xiang Ye, PhD, Suba Rajendren, PhD, Antiana Richardson, and John Karijolich, PhD, are studying how the cancer-causing virus KSHV commandeers host gene expression and regulatory machinery.
April 20, 2023

Study details RNA editing in virus-infected cancer cells

Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.

Child ambassador Brody Reiner drops the puck at the Hockey Fights Cancer game March 25. Brody, a patient of Monroe Carell Jr. Children’s Hospital at Vanderbilt, is joined on the ice by retired goalie Pekka Rinne, Predators player Colton Sissons, left, and Seattle Kraken player Yanni Gourde.
April 13, 2023

Predators’ support in battling childhood cancer stays strong

The Nashville Predators, including retired goalie Pekka Rinne, recently visited Monroe Carell Jr. Children’s Hospital at Vanderbilt to present hospital leaders with the proceeds raised throughout the year from the team’s 365 Pediatric Cancer Fund presented by Twice Daily.

April 12, 2023

Research identifies new target that may prevent blood cancer

An international coalition of biomedical researchers co-led by Vanderbilt’s Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer.